Trust Endures, Digital Intelligence Upgrades | Zhenge Bio & Morimatsu Mo-EAMaster Phase II Project Officially Launched

On January 9, 2026, the 'Mo-EAMaster Phase II Project Kick-off Meeting' between Morimatsu Life Technology and Zhenge Bio was successfully held. Following the successful implementation of Phase I, both parties have joined hands again to draw a new blueprint for digital intelligence upgrades in pharmaceutical industry asset management.

In their first collaboration, Morimatsu used its mature Mo-EAMaster solution to fully digitize Zhenge Bio’s equipment management processes:

🔹 Achieved digital record-keeping for equipment ledgers and standardized maintenance processes, eliminating the pain point of scattered information typical of traditional management methods;

🔹 Enabled end-to-end online data flow for equipment from registration to operation, maintenance, and retirement, integrating it into a unified control 'data pool';

🔹 Significantly improved Overall Equipment Effectiveness (OEE), fully strengthening the foundation for compliant operations, laying a solid groundwork for deeper cooperation in Phase II.

🔹 Compliance FirstDeep alignment with the ISO55000 international standard and GMP-related guidelines, meeting industry compliance requirements throughout the entire process;

🔹 Full lifecycle coverage:Provides a closed-loop full lifecycle management for equipment from acceptance and accounting, installation, operation and maintenance to retirement;

🔹 Efficient collaboration:Supports multi-terminal interaction on Web, mobile, and H5 platforms, featuring an equipment dashboard and data visualization panels that integrate core functions such as repair, maintenance, calibration, and spare parts management, achieving dual improvements in 'refined management + convenient operation'.

This second-phase project focuses on operational pain points, leveraging a two-pronged approach of “new feature additions + experience optimization,” concentrating on precision upgrades across four modules, injecting more precise and efficient digital intelligence into full lifecycle equipment management.

✅ Maintenance Module:New features adapted to actual operation and maintenance needs, optimizing fault handling processes and work order management. Paired with a maintenance knowledge base, it improves problem-solving efficiency and reduces unplanned downtime.

✅ Calibration Module:Added dynamic adjustment-related functions, standardizing calibration records and task assignments to ensure compliance with GMP requirements, achieving full traceability of the calibration process.

✅ Maintenance Module:Improved closed-loop formulation and execution of maintenance plans, upgraded to-do service reminder mechanisms, and optimized multi-terminal collaboration experience, making maintenance work more standardized and responsive.

✅ Patrol Inspection Module:Promoting the transition of inspection data from offline to online storage and management, ensuring data traceability and verifiability, and optimizing overall process management efficiency.

The project follows clear milestones such as requirement analysis, feature development, CSV validation, and acceptance. Sumitomo and Zhenge have clearly defined responsibilities, ensuring collaboration through diverse communication mechanisms. Immediate actions are synchronized while risks are anticipated, fully supporting steady project implementation.

In the future, Morimatsu Life Science and Zencore Biologics will take the Phase II project as a new starting point to further deepen collaboration. Relying on the technical advantages and full-scenario functionality of the Mo-EAMaster system, they will implement digital and intelligent management to help companies strengthen compliance, improve operational efficiency, and jointly empower the intelligent transformation of asset management in the pharmaceutical industry, writing a new chapter of win-win cooperation!

Shanghai Zencore Biologics Co., Ltd. (hereinafter referred to as 'Zencore Biologics') provides comprehensive CDMO services from preclinical development to commercial production. Its core businesses cover large molecule biopharmaceutical CDMO, antibody-drug conjugates (ADC) CDMO, catalog media, custom media development and production services, analytical testing services, quality, and regulatory services, accelerating the R&D and commercialization process of large molecule biopharmaceuticals for global pharmaceutical companies and research institutions.

Zencore Biologics consistently adheres to the values of 'Pursuit of Excellence and Perfection,' providing high-quality and efficient CDMO services to global partners. It empowers customers to quickly transform products from concept to commercial production, integrating advanced technologies to create affordable medicines that benefit everyone.